amantadine has been researched along with Brain Injury, Chronic in 3 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Brain Injury, Chronic: Conditions characterized by persistent brain damage or dysfunction as sequelae of cranial trauma. This disorder may result from DIFFUSE AXONAL INJURY; INTRACRANIAL HEMORRHAGES; BRAIN EDEMA; and other conditions. Clinical features may include DEMENTIA; focal neurologic deficits; PERSISTENT VEGETATIVE STATE; AKINETIC MUTISM; or COMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine 400 mg was administered per day." | 2.71 | Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). ( Butters, M; Dixon, E; Donnell, AJ; Kraus, MF; Marion, D; Smith, GS; Yilong, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hammond, FM | 1 |
| Sherer, M | 1 |
| Malec, JF | 1 |
| Zafonte, RD | 1 |
| Dikmen, S | 1 |
| Bogner, J | 1 |
| Bell, KR | 1 |
| Barber, J | 1 |
| Temkin, N | 1 |
| Kraus, MF | 1 |
| Smith, GS | 1 |
| Butters, M | 1 |
| Donnell, AJ | 1 |
| Dixon, E | 1 |
| Yilong, C | 1 |
| Marion, D | 1 |
| Shiller, AD | 1 |
| Burke, DT | 1 |
| Kim, HJ | 1 |
| Calvanio, R | 1 |
| Dechman, KG | 1 |
| Santini, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Parallel-Group, Randomized, Double-Blind, Placebo-Controlled Trial of Amantadine Hydrochloride in the Treatment of Chronic Traumatic Brain Injury Irritability and Aggression: A Replication Study[NCT00779324] | 168 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| Evaluation and Diagnosis of Potential Research Subjects With Traumatic Brain Injury (TBI)[NCT01287156] | 1,328 participants (Actual) | Observational | 2013-01-10 | Completed | |||
| Biomarkers-Driven Development of Experimental Therapeutics for Traumatic Brain Injury[NCT01420939] | 19 participants (Actual) | Observational | 2011-07-21 | Terminated | |||
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -4 |
| Placebo | -4 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -5 |
| Placebo | -4 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -3 |
| Placebo | -2 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -3 |
| Placebo | -2 |
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00779324)
Timeframe: 28 Days
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | 3.00 |
| Placebo | 3.00 |
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00779324)
Timeframe: 60 days
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | 3.00 |
| Placebo | 3.00 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 66.3 |
| Placebo | 66.7 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 51.3 |
| Placebo | 40.5 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 60.5 |
| Placebo | 48.8 |
As described above for the primary measure, assessed as a secondary measure at Day 60. The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: 60 days
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 74.7 |
| Placebo | 68.3 |
2 trials available for amantadine and Brain Injury, Chronic
1 other study available for amantadine and Brain Injury, Chronic
| Article | Year |
|---|---|
Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years' duration.
Topics: Adolescent; Amantadine; Brain Injury, Chronic; Craniocerebral Trauma; Dopamine Agents; Humans; Male; | 1999 |